Lion TCR
Blood & Organ Banks · Singapore · 11-50 Employees
View Company Info for Free
Overview
Headquarters
77 Ayer Rajah Cres 01-29, Singapore, Cen...Phone Number
+65 69260818Website
www.liontcr.comRevenue
<$5 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
2
2
2
2
2
About Lion TCR
Lion TCR specializes in developing innovative immunotherapies, particularly T cell receptor (TCR)-T cell therapy, to combat HBV-related hepatocellular carcinoma and other viral infections prevalent in Asia. With a focus on harnessing the patient's immune system, their proprietary therapy has demonstrated proven clinical safety and efficacy, significantly improving survival rates for liver cancer patients. The company boasts the largest patented TCR library globally, covering a wide range of HLA types, and operates a state-of-the-art GMP production facility for clinical applications. Lion TCR is committed to ongoing clinical trials and research collaborations to advance their therapeutic offerings.Explore more
Lion TCR Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lion TCR your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Lion TCR launches new products
Lion TCR, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Lion TCR has new funding data
Congratulate Masked Content for being promoted to Masked Content at Lion TCR
Check if Lion TCR has recently received funding, and reach out quickly before it becomes old news!
Check out if Lion TCR is spiking on competitors!
Click to see if Lion TCR had a recent Job posting/layoffs
Earning: See what the market has to say on Lion TCR recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Lion TCR
Find 2 more new buyers
Company Profile Activity
Activity Insights
Lion TCR is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Lion TCR is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Lion TCR.
Lion TCR financials insights
Gather financial insights about Lion TCR, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Other Financing Round
$20M
Lion TCR Tech Stack
A closer look at the technologies used by Lion TCR
Lion TCR News & Media
Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma
SINGAPORE, Feb. 12, 2025 /PRNewswire/ -- On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international multicenter Phase 2 clinical trial. This significant progress further solidifies Lion TCR's leading position in the mRNA-based TCR-T field and brings new hope to patients with hepatocellular carcinoma (HCC). U.S. Food and Drug Administration HeLion TCR clinched the prestigious T-Up Excellence Awards in Singapore
SINGAPORE, Nov. 2, 2023 /PRNewswire/ -- At the annual Singapore Week of Innovation and Technology (SWITCH) 2023, Lion TCR, a clinical-stage mRNA-based T cell immunotherapy company, is thrilled to announce a significant milestone of clinching the T-Up Excellence Awards. This award, in recognition of remarkable contributions to the growth and innovation within Lion TCR and the broader Singapore biotech sector, have been also presented to Dr. Wai Lu-En, Lion TCR's Senior Director of Research andLion TCR Secures USD 40 million Series B2 Financing, Revolutionizing Solid Tumor Treatment with mRNA-Encoding TCR-T Cell Therapy
SINGAPORE and GUANGZHOU, China, June 27, 2023 /PRNewswire/ -- 27 June 2023, Lion TCR, a clinical-stage T-cell immunotherapy company, is thrilled to announce the successful completion of its USD 40 million Series B2 financing round. Guangzhou Industrial Investment and Capital Operation Holding Group Ltd. led the financing with participation from Guangzhou Guoju Investment and CSPC NARD Capital Fund. The funds raised will be used primarily to support Lion TCR's clinical trials on hepatitis B virusLion TCR Announces FDA IND Clearance for its LioCyx-M004 for Hepatocellular Carcinoma
SINGAPORE and Guangzhou, China and LOS ANGELES, Sept. 23, 2021 /PRNewswire/ -- Lion TCR Pte Ltd, a clinical-stage biotech company specialized in T Cell Receptor (TCR) T cell therapy today announced that it has received clearance from U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) Application for LioCyx-M004, autologous T-cells transfected with mRNA encoding Hepatitis B surface antigen (HBsAg) specific TCR. Lion TCR intends to initiate a Phase 1b/2 multi-center stu
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lion TCR
Sign Up For FreeTo access detailed company insights
Lion TCR specializes in developing innovative immunotherapies, particularly T cell receptor (TCR)-T cell therapy, to combat HBV-related hepatocellular carcinoma and other viral infections prevalent in Asia. With a focus on harnessing the patient's immune system, their proprietary therapy has demonstrated proven clinical safety and efficacy, signifi... Read More
